Dutton Associates Announces Investment Opinion: Pluristem Therapeutics Rated Speculative Buy in Update Report by Dutton Associates
ROSEVILLE, Calif., Jan 22, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Pluristem Therapeutics, Inc. (Nasdaq:PSTI), with a Speculative Buy rating and 12-month price target of $6.50. The 17-page report by Dutton Associates senior analyst Denise T. Resnik is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals. Pluristem Therapeutics' innovative cell therapy technology has the potential to enable blood from the umbilical cord and the placenta (retrieved after the birth of a baby) to become a viable alternative to stem cells harvested from donor bone marrow, with its intrinsic problems. While validation of the Company's technology is still in the pre-clinical stage, we believe that, if the technology proves to be successful, the impact on the patient population requiring bone marrow transplant would be significant, especially as therapeutic uses for such transplants continue to be discovered. As the Company makes progress in its clinical program -- specifically filing for Food and Drug Administration permission to conduct Phase 1 trials and commencing those trials -- we believe the shares will respond favorably.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, have expertise in many industries. Dutton Associates provides continuing analyst coverage of 110 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The current cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $52,000 from the Company for 6 Research Reports with coverage commencing on 9/6/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing. |
